Unexpected uterine sarcomas after hysterectomy and myomectomy for presumed leiomyoma: a retrospective study of 26,643 patients

Objectives We conducted this study to explore the clinical characteristics, prognosis, and prevalence of unexpected uterine sarcoma (UUS) after hysterectomy and myomectomy for presumed leiomyoma. Study design The records of women who underwent hysterectomy or myomectomy through laparoscopy or laparotomy for preoperatively presumed uterine leiomyomas from January 2009 to December 2016 were reviewed and data were retrospectively analyzed. Results Eleven patients had morcellation of uterine sarcoma. Eighty-eight patients were diagnosed with uterine sarcomas (total prevalence: 0.33%) including 29 leiomyosarcomas (LMS), 48 endometrial stromal sarcomas (ESS), and 11 adenosarcomas. ESS patients with advanced stage were significantly associated with worse overall survival (p<0.01). Conclusion Only 0.33% of patients who underwent surgery for presumed leiomyoma experienced UUS, and advanced stage seemed to be the single prognostic factor for sarcoma. However, the time interval between initial treatment and secondary definitive surgery was not shown to impact prognosis. In addition, the small number of UUS patients having morcellation (4 LMS and 7 ESS) may be underpowered to detect differences in survival.

[1]  Lu-Wen Wang,et al.  Proportion of Uterine Malignant Tumors in Patients with Laparoscopic Myomectomy: A National Multicenter Study in China , 2017, Chinese medical journal.

[2]  W. C. Ang,et al.  Incidence of Malignancy and Myoma Variants at Surgery for Presumed Benign Symptomatic Myomas. , 2017, Journal of minimally invasive gynecology.

[3]  B. Seagle,et al.  Prognosis and treatment of uterine leiomyosarcoma: A National Cancer Database study. , 2017, Gynecologic oncology.

[4]  K. Pavlakis,et al.  Morcellating uterine mesenchymal tumors: The pathologist's view , 2017, The journal of obstetrics and gynaecology research.

[5]  K. Nawapun,et al.  Undiagnosed Uterine Sarcomas Identified During Surgery for Presumed Leiomyoma at a National Tertiary Hospital in Thailand: A 10-Year Review , 2017, International Journal of Gynecologic Cancer.

[6]  T. Pawlik,et al.  Association of Optimal Time Interval to Re-resection for Incidental Gallbladder Cancer With Overall Survival: A Multi-Institution Analysis From the US Extrahepatic Biliary Malignancy Consortium , 2017, JAMA surgery.

[7]  N. Fleming,et al.  Uterine Adenosarcoma: a Review , 2016, Current Oncology Reports.

[8]  Young Tae Kim,et al.  Outcomes of uterine sarcoma found incidentally after uterus-preserving surgery for presumed benign disease , 2016, BMC Cancer.

[9]  B. Rueda,et al.  The Epidemiology and Genetics of Uterine Leiomyoma. , 2016, Best practice & research. Clinical obstetrics & gynaecology.

[10]  P. G. Paul,et al.  Uterine Sarcomas in Patients Undergoing Surgery for Presumed Leiomyomas: 10 Years' Experience. , 2016, Journal of minimally invasive gynecology.

[11]  T. Raine-Bennett,et al.  Occult Uterine Sarcoma and Leiomyosarcoma: Incidence of and Survival Associated With Morcellation , 2016, Obstetrics and gynecology.

[12]  D. Richardson,et al.  Risk of Occult Uterine Sarcoma in Women Undergoing Hysterectomy for Benign Indications , 2015, Obstetrics and gynecology.

[13]  J. Lang,et al.  Clinical Characteristics and Prognosis of Unexpected Uterine Sarcoma After Hysterectomy for Presumed Myoma With and Without Transvaginal Scalpel Morcellation , 2015, International Journal of Gynecologic Cancer.

[14]  Q. Yang,et al.  Incidence and clinical characteristics of unexpected uterine sarcoma after hysterectomy and myomectomy for uterine fibroids: a retrospective study of 10,248 cases , 2015, OncoTargets and therapy.

[15]  M. Pascual,et al.  Impact of Surgery on the Evolution of Uterine Sarcomas. , 2015, Journal of minimally invasive gynecology.

[16]  S. Blank,et al.  Uterine carcinosarcoma: A review of the literature. , 2015, Gynecologic oncology.

[17]  J. Kennedy,et al.  Uterine sarcomas and parasitic myomas after laparoscopic hysterectomy with power morcellation. , 2015, American journal of obstetrics and gynecology.

[18]  M. Lieng,et al.  Risk of morcellation of uterine leiomyosarcomas in laparoscopic supracervical hysterectomy and laparoscopic myomectomy, a retrospective trial including 4791 women. , 2015, Journal of minimally invasive gynecology.

[19]  S. As-Sanie,et al.  Unexpected Gynecologic Malignancy Diagnosed After Hysterectomy Performed for Benign Indications , 2015, Obstetrics and gynecology.

[20]  Kathryn H Schmitz,et al.  Quality of Life, Body Mass Index, and Physical Activity Among Uterine Cancer Patients , 2014, International Journal of Gynecologic Cancer.

[21]  Yuan Gao,et al.  Retrospective analysis of 80 cases with uterine carcinosarcoma, leiomyosarcoma and endometrial stromal sarcoma in China, 1988-2007. , 2014, International journal of clinical and experimental pathology.

[22]  B. Quade,et al.  The value of re-exploration in patients with inadvertently morcellated uterine sarcoma. , 2014, Gynecologic oncology.

[23]  J. Segars,et al.  The estimated annual cost of uterine leiomyomata in the United States. , 2012, American journal of obstetrics and gynecology.

[24]  Sun-Kyung Park,et al.  The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma. , 2011, Gynecologic oncology.

[25]  M. Rijn,et al.  Uterine leiomyosarcomas: tumor size, mitotic index, and biomarkers Ki67, and Bcl-2 identify two groups with different prognosis. , 2011, Gynecologic oncology.

[26]  D. Baird,et al.  New Directions in the Epidemiology of Uterine Fibroids , 2010, Seminars in reproductive medicine.

[27]  J. Prat,et al.  Uterine sarcomas: a review. , 2010, Gynecologic Oncology.

[28]  J. Prat FIGO staging for uterine sarcomas , 2009, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[29]  J. Nesland,et al.  Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients , 2009, Histopathology.

[30]  C. Walker,et al.  Uterine Fibroids: The Elephant in the Room , 2005, Science.

[31]  B. Mellado,et al.  Is vascular and lymphatic space invasion a main prognostic factor in uterine neoplasms with a sarcomatous component? A retrospective study of prognostic factors of 60 patients stratified by stages. , 2002, International journal of radiation oncology, biology, physics.

[32]  P. Freitag [Uterine sarcomas]. , 1997, Ceska gynekologie.

[33]  M. K. Hardiman Routine hysterectomy for large asymptomatic uterine leiomyomata: a reappraisal. , 1992, Obstetrics and gynecology.

[34]  Z. Petrovich,et al.  Treatment of uterine sarcomas , 1990, Cancer.